Synergistic drug combinations and machine learning for drug repurposing in chordoma

Edward Anderson¹, Tammy M. Havener¹, Kimberley M. Zorn², Daniel H. Foil², Thomas R. Lane², Stephen J. Capuzzi¹, Dave Morris¹, Anthony J. Hickey¹,³, David H. Drewry⁴ & Sean Ekins¹,²*

Chordoma is a devastating rare cancer that affects one in a million people. With a mean-survival of just 6 years and no approved medicines, the primary treatments are surgery and radiation. In order to speed new medicines to chordoma patients, a drug repurposing strategy represents an attractive approach. Drugs that have already advanced through human clinical safety trials have the potential to be approved more quickly than de novo discovered medicines on new targets. We have taken two strategies to enable this: (1) generated and validated machine learning models of chordoma inhibition and screened compounds of interest in vitro. (2) Tested combinations of approved kinase inhibitors already being individually evaluated for chordoma. Several published studies of compounds screened against chordoma cell lines were used to generate Bayesian Machine learning models which were then used to score compounds selected from the NIH NCATS industry-provided assets. Out of these compounds, the mTOR inhibitor AZD2014, was the most potent against chordoma cell lines (IC₅₀ 0.35 µM U-CH1 and 0.61 µM U-CH2). Several studies have shown the importance of the mTOR signaling pathway in chordoma and suggest it as a promising avenue for targeted therapy. Additionally, two currently FDA approved drugs, afatinib and palbociclib (EGFR and CDK4/6 inhibitors, respectively) demonstrated synergy in vitro (CI₅₀ = 0.43) while AZD2014 and afatinib also showed synergy (CI₅₀ = 0.41) against a chordoma cell in vitro. These findings may be of interest clinically, and this in vitro- and in silico approach could also be applied to other rare cancers.

Chordoma is a rare cancer that occurs in the bones of the skull base and spine which is part of a larger class of tumors known as sarcomas. Chordoma tumors develop from cells of the notochord, an embryonic structure that facilitates development of the spine¹. The notochord disappears when the fetus is about 8 weeks old, but some notochord cells remain in the bones of the spine and skull base¹. This is a rare occurrence, but when they do, these cells can turn into chordoma. A chordoma tumor usually grows slowly without symptoms for years before diagnosis, which is often in the 5th and 6th decades of life (although it can occur at any age). Studies have demonstrated that skull base chordomas are observed more often in children, whilst spinal chordomas are more frequently observed later in life²⁻⁴. It has also been described that when chordomas metastasize they frequently distribute to the lungs, liver, bones, or lymph nodes. This occurs in 30 to 40 percent of people where the tumor metastasizes to other parts of the body². At this point in time there are no known environmental, dietary or lifestyle risk factors for this rare type of cancer. Chordomas often occur at random with no direct inherited genetic trait, however familial cases can be caused by duplications of the brachyury gene⁴. A SNP in the brachyury gene occurs in 95 percent of people with this tumor⁵,⁶, and furthermore, chordomas have been reported at a higher incidence in children diagnosed with the genetic disease Tuberous Sclerosis Complex (TSC)⁷. With a mean-survival rate of just 6 years and poor response to current medications, surgical resection is the main course of treatment². Patients therefore need new and effective drugs to expand their treatment options and improve survival rates.

¹UNC Catalyst for Rare Diseases, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ²Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC, USA. ³RTI International, Research Triangle Park, NC, USA. ⁴Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. *email: sean@collaborationspharma.com
Chordoma tumors, which occur in both pediatric and adult populations, are known to overexpress multiple kinases. Kinases are a family of ~500 proteins, collectively known as the kinome, integral for a multitude of cellular functions relevant to cancer pathogenesis. In a 2013 study, a tissue microarray containing 58 chordomas was used to examine the expression of the kinases PDGFR-α, PDGFR-β, EGFR, c-Met, c-Kit, pAKT, mTOR, and HER2. Most tumors were positive by immunohistochemistry for PDGFR-α (92%), PDGFR-β (85%), c-Kit (77%), c-Met (96%), pAKT (82%), mTOR (56%), HER2 (24%), and EGFR (26%), yet imatinib, an FDA-approved drug that inhibits PDGFR-α, PDGFR-β, and c-Kit, has shown little to no efficacy in chordoma in vivo models.

A body of such molecular, preclinical, and clinical evidence of interest to chordoma oncogenesis has begun to emerge for several kinases: Epidermal Growth Factor Receptor (EGFR), Cyclin-dependent kinase 4 (CDK4), Cyclin-dependent kinase 6 (CDK6) and the mammalian target of rapamycin (mTOR). These kinases are well-studied in the field of oncology, with several FDA-approved drugs on the market targeting each kinase and they may serve as drug repurposing candidates for the treatment of chordoma.

Drug repurposing or repositioning is an approach whereby new therapeutic uses for existing drugs or clinical candidates are identified. High throughput screens, virtual screening or serendipitous observations are employed to enable drug repurposing. For example we have previously identified approved drugs active against the Ebola virus and Chagas Disease using Bayesian and other machine learning models. In addition, there are several ongoing efforts to demonstrate new uses for molecules that have been through clinical trials for other uses but were subsequently shelved. One such example is the NIH NCATS industry-provided assets that could be potentially repurposed.

Further, two FDA-approved kinase inhibitor drugs—palbociclib, a breast cancer drug, and afatinib, a non-small cell lung carcinoma drug—have shown equally robust efficacy in patient derived xenograft (PDX) and cell-line derived xenograft (CDX) models of chordoma. Palbociclib and afatinib are designed to specifically target different kinases, CDK4/6 and EGFR, respectively. The utility of each in preclinical chordoma models implies that multiple oncogenic biological pathways may drive chordoma as is true in many other cancers.

We hypothesized that combinations of clinical kinase inhibitors in chordoma models and patients may act additively or synergistically by dampening oncogenic signaling in multiple pathways. Both primary targets and secondary targets can play a role in this. A combination therapy of afatinib and palbociclib is of particular interest but there may also be many other potential combinations of kinase inhibitors. Chordoma PDX and CDX mouse models respond equally well to afatinib and palbociclib, though these drugs target divergent and minimally overlapping regions of the kinome. A combination of EGFR/CDK inhibitors, i.e., afatinib/palbociclib, may target multiple oncogenic signaling pathways simultaneously. Following the same rationale, we now evaluate the in vitro efficacy of EGFR/CDK inhibitor combinations prior to future in vivo PDX and CDX mouse model studies. We envision that these proposed studies will enable and support future drug combination chordoma clinical trials.

Results

Machine learning models for chordoma drug discovery. Several recently published studies of compounds screened against chordoma cell lines were used to generate Bayesian machine learning models with our Assay Central software. In one published chordoma study 1097 compounds were screened against 3 chordoma cell lines (U-CH1, U-CH2, MUG-Chor1) and 27 had chordoma selective cytotoxicity and many of these were EGFR inhibitors. A more recent study from the Broad Institute and collaborators profiled 459 com-
pounds in 4 chordoma cell lines (JHC7, MUG-Chor1, U-CH1, UM-Chor1) and identified 28 potent antiproliferative compounds with several kinase inhibitors including CDK 7/12/13 inhibitors. These data sets (which for ease we have called EGFR or Broad) were used either separately or combined to generate machine learning models that were evaluated with fivefold cross validation (Table 1, Figure S1). These models were also used to score the 3 molecules not in these training sets (Table 2 and Fig. 1C,D) and their scores would suggest the value of testing them in vitro. The atom coloring feature helps to suggest which molecule features correspond to activity with a particular model [e.g. with the EGFR model AZD2014 has a large area of the molecule colored green (favorable for activity) while the other molecules have fewer green colored atoms (Fig. 2A–C)].

In vitro studies. We tested AZD2014 (Fig. 1C), RDEA119 (Fig. 1D), AZD4054 (Fig. 1E) AZD0530, (Fig. 1F) in UCH1 and UCH2 cell lines, along with known chordoma inhibitors afatinib and palbociclib, using reduction of resazurin to resarufin as an assay for metabolic activity of chordoma cell lines. As previously reported, afatinib is a potent inhibitor of U-CH1, but not U-CH2. The Bayesian model we have termed 'EGFR' correctly predicted the rank order of these 3 compounds not in the training sets (Table 2). Of the drugs predicted by our model, AZD2014 was the most potent against both cell lines (IC50 0.35 µM U-CH1 and 0.61 µM U-CH2, Table 3 and Fig. 3A,B), though maximal inhibition of U-CH2 cells was limited. AZD0530 and RDEA119 also showed moderate potency against U-CH1 (IC50 1.5 µM and 2.4 µM, respectively) but not U-CH2. AZD4054 had low potency, but even at 11 µM this was unexpected given that its target, the endothelin A receptor, has no known functions in chordoma.

In vitro studies—combination studies of approved drugs. Next we tested the combinations of drugs used in this study to determine whether inhibition of multiple biological pathways would result in synergistic effects on chordoma cell lines. In order to determine this we calculated the combination index (CI) for each of the pairs of drugs mixed at different ratios, where CI < 1 indicates a synergistic effect. For each of the pairs of drugs used, CI was then calculated using five eight-point dose curves, each with a constant ratio of the two drugs. In U-CH1 cells, we observed substantial synergy between afatinib and palbociclib (CI = 0.43, 95% CI 0.28–0.66, Fig. 4A, Table 4). We also observed substantial synergy between afatinib and AZD2014 (CI = 0.41, 95% CI 0.34–0.78, Fig. 4B). The combination of AZD0530 and AZD2014 showed more modest synergy (CI = 0.77, 95% CI 0.67–0.88, Fig. 4C), while the combination of palbociclib and AZD0530 had weak but detectable synergy (CI50 = 0.61, 95% CI 0.49–0.77, Fig. 4D). However, in U-CH2 cells, we did not observe synergistic effects in any tested combinations (Table 5).

Discussion

Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase (RTK). Activation of EGFR leads to the phosphorylation of proteins in downstream signaling pathways, including the PI3k-Akt-mTOR and RAS-RAF-MEK-MAPK pathways. Both of these pathways are critical in regulating cellular apoptosis, proliferation, migration, and survival. Broadly speaking, over-expression of EGFR, which is located on chromosome 7p12, can increase cellular proliferation and contribute to aggressive tumor behavior. Within the molecular context

| Model name | Actives | Size | ROC | F1 | Kappa | MCC | Domain |
|------------|---------|------|-----|----|-------|-----|--------|
| Broad      | 150     | 454  | 0.67| 0.54| 0.23  | 0.25| 0.36   |
| Broad + EGFR| 289   | 1486 | 0.81| 0.52| 0.36  | 0.39| 0.33   |
| EGFR       | 147     | 1064 | 0.84| 0.44| 0.30  | 0.37| 0.28   |

Table 1. Chordoma Bayesian model statistics. Datasets were named as "Broad"21 and "EGFR"20, and underwent curation to remove problematic molecules before model building. Data represent fivefold cross validation. The “Broad” dataset is named as such because the data came from a chordoma screen at the Broad Institute. The "EGFR" data set is so named because it came from a paper that highlighted the activity of EGFR compounds in chordoma and is not meant to construe a dataset made up entirely of EGFR compounds. Both datasets contain a wide variety of compounds that inhibit a broad range of targets.

| Compound | Broad Bayesian score | Broad model applicability | Broad/EGFR Bayesian score | Broad/EGFR model applicability | EGFR Bayesian score | EGFR model applicability |
|----------|----------------------|--------------------------|---------------------------|-------------------------------|---------------------|--------------------------|
| AZD2014  | 0.46                 | 0.91                     | 0.56                      | 0.96                          | 0.67                | 0.82                     |
| RDEA11   | 0.62                 | 0.66                     | 0.66                      | 0.67                          | 0.60                | 0.57                     |
| AZD4054  | 0.53                 | 0.53                     | 0.50                      | 0.60                          | 0.55                | 0.55                     |

Table 2. Bayesian Machine Learning predictions for chordoma activity for compounds not in the training sets. Datasets were named as Broad21 and EGFR20 and models are described in Table 1. Model applicability assesses the portion of fragments overlapping with the training set molecules, higher values indicate more fragments overlapping with the training set. The ‘score’ is the prediction score, a measure of probability of activity with higher values being desirable.
of chordoma, copy number variations at chromosome 7, i.e., gains and partial polysomies, are commonly observed in chordoma, and EGFR gene copy number variations are likewise observed. Several FDA-approved and clinical kinase inhibitors whose main therapeutic target is EGFR have been tested in preclinical in vitro and in vivo models of chordoma. Gefitinib and erlotinib, two FDA-approved EGFR inhibitors used in the treatment of non-small-cell lung carcinoma (NSCLC), individually inhibited U-CH1, U-CH7, UM-Ch-SCor1, and MUG-Chor1 cellular proliferation in dose-dependent manners. Afatinib, another FDA-approved EGFR inhibitor used against NSCLC, had anti-proliferative activity against all chordoma cell lines tested (IC50 < 0.7 µM) except for JHC7. Afatinib was also found to promote degradation of EGFR and brachyury, both of which are crucial to chordoma cell growth. In vivo studies for erlotinib and afatinib have been reported. Erlotinib treatment significantly lowered tumor volume relative to controls in a PDX mouse model and reduced p-EGFR. Afatinib treatment resulted in tumor growth inhibition in three PDXs and one CDX with no signs of toxicity in any of the mouse models. In addition to this preclinical data, some clinical evidence exists to support EGFR and its therapeutic agents as potential chordoma treatments. A retrospective study found the median PFS was ~ 15.0 months for five patients treated with erlotinib. For afatinib, there is currently an open clinical trial in the Netherlands (NCT03083678) to evaluate its efficacy against locally advanced and metastatic chordoma.
Cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are serine-threonine kinases. CDK4/6 are known oncoproteins, as upregulation of these kinases or inactivation of CDKN2A lead to cell cycle deregulation, increased cell proliferation, and tumorigenesis. CDK4/6 functions downstream of a number of oncogenic pathways, implying that CDK4/6 inhibition may be effective when combined with inhibitors of the upstream pathways. Combination treatment of an EGFR sensitive non-small cell lung cancer PDX model with a CDK4/6 inhibitor and an EGFR inhibitor showed combinatorial benefit, providing precedent for a similar application in chordoma tumors which are also sensitive to EGFR inhibition. In another study, palbociclib sensitized lung cancer cells to treatment with EGFR inhibitors. Importantly, in chordoma the CDK4/6 regulatory gene CDKN2A (also known as p16) is frequently lost. CDK4/6 are thus found in an over-activated state in chordoma. From a gene expression perspective, CDK4 and CDK6 mRNAs have been detected in all eight chordoma cell lines that were interrogated: U-CH1, U-CH2, U-CH3, U-CH6, U-CH7, U-CH10, U-CH11, and U-CH12. Likewise, CDK4 and CDK6 protein were observed in the same eight chordoma cell line as above. An immunohistochemistry study of 25 patient samples showed CDK4 was overexpressed in 20% of cases. Tissue microarray analysis of 85 samples from 72 chordoma patients found that ~ 98% of tissue samples expressed CDK4. Additionally, the mean expression level of CDK4 was significantly higher for non-survivors than survivors at the time of publication. There are three FDA-approved kinase inhibitors whose main therapeutic targets are CDK4/6. Palbociclib, one of these dual CDK4/6 inhibitors, has been tested extensively in preclinical in vitro and in vivo models of chordoma. Palbociclib treatment resulted in decreased cell growth in a dose-responsive manner for all eight chordoma cell lines tested. In PDX and CDX models, treatment with palbociclib resulted in significant inhibition of tumor growth in 5/6 individual models (Table S1). There is currently a clinical trial enrolling in Germany (NCT03110744) to evaluate the efficacy of palbociclib against locally advanced and metastatic chordoma.

mTOR is a serine threonine kinase which is a member of two protein complexes, mTOR complex 1 (mTORC1) and complex 2 (mTORC2). By virtue of these interactions it plays key roles in a variety of cellular processes including metabolism and proliferation. It lies in the PI3K–AKT–mTOR signaling pathway, and components of this pathway are implicated in a wide range of cancers. Chordoma is no exception. Analysis of 50 chordomas showed that a high percentage of tumors were positive for p-AKT, pTSC2, p-mTOR, p-P70S6K, p-RPS6, p-4EBP1 and eIF-4E. These are all linked to the complicated mTOR signaling pathway. The authors suggested that a majority of chordomas may respond to mTOR inhibitors or mTOR inhibitors in combination with other drugs. A loss of PTEN (a tumor suppressor which negatively regulates this PI3K-AKT-MTOR pathway) was also observed in 16% of these chordoma cases. A study of chordoma tumors from 111 patients demonstrated that three key proteins in the mTOR pathway (p4EBP1, pS6-Ser240/244, pS6-Ser235/236) were activated in 46% of the tumors. In a different study of just skull base chordoma, expression of PI3 and AKT pathway genes was significantly upregulated in brachury high expression tumors. Importantly, the transcription factor brachyury (gene name TBXT), a key driver of chordoma, seems linked to this pathway. The U-CH2 cell line is inhibited by

---

**Figure 3.** Representative dose response curves for compounds tested against chordoma cell lines in vitro. Molecules were tested in (A) U-CH1 cells and (B) U-CH2 cells. Graphs produced with R version 3.6.2 (https://cran.r-project.org/), with the following packages: drc version 3.0–6 for general dose–response curve fitting and analysis, medrc 1.1–0 for mixed-effects modeling of dose–response data, multcomp 1.4–11 for multiple comparison testing, and ggplot2 3.2.1 for plotting.
the dual PI3k/mTOR inhibitor BEZ-235, but not the mTORC1-specific inhibitor rapamycin. Given our observations that U-CH2 is inhibited by AZD2014, a highly specific inhibitor of mTOR which inhibits both mTORC1 and mTORC2 activity, we hypothesize that mTORC2 has a critical role in promoting chordoma proliferation or survival. An analysis of sacral chordomas demonstrated that mTOR expression levels were significantly higher than in adjacent normal tissue. The PI3K-mTOR pathway is also upregulated in the UCH-1 chordoma cell line. A PI3K/mTOR inhibitor inhibited both AKT and MTOR activation in this cell line. The compound inhibited proliferation and induced apoptosis. Finally, the MTOR inhibitor MLN0128 (sapanisertib) decreased activity of the PI3K-AKT-MTOR pathway in vivo in a clival chordoma PDX model. Taken together, clearly this pathway is consistently dysregulated in chordomas, and a promising avenue for targeted therapy. Additionally, it has been observed clinically that in one patient, rapamycin, an FDA-approved mTOR inhibitor, slowed the progression of a recurrent chordoma tumor. The utility of these various kinase inhibitors in preclinical and clinical chordoma settings implies that multiple oncogenic biological pathways may drive chordoma.

Based on these observations, we hypothesized that combinations of clinical EGFR, CDK, and mTOR inhibitors may act synergistically by dampening oncogenic signaling in multiple pathways. Using a combination of

Figure 4. Isobolograms for combinations of compounds demonstrating significant synergy. (A) palbociclib and afatinib, (B) AZD2014 and afatinib, (C) AZD2014 and AZD0530, (D) AZD0530 and palbociclib. The Loewe Additivity isobole is shown as the diagonal grey line, representing the expected IC_{50} of non-interacting combinations of drugs. Measured absolute IC_{50} of drug combinations (black line and solid dots) represent the isobole of dose combinations with equivalent activity, with dashed lines and open dots indicating the 95% confidence band. Points below and to the left of the isobole indicate a synergistic drug interaction. Graphs produced with R version 3.6.2 (https://cran.r-project.org/), with the following packages: drc 3.0–6 for general dose–response curve fitting and analysis, medrc 1.1–0 for mixed-effects modeling of dose–response data, multcomp 1.4–11 for multiple comparison testing, and ggplot2 3.2.1 for plotting.
computational and in vitro approaches we have identified AZD2014 (targets mTORC1 and mTORC2), RDEA119 (targets MEK1/2), and AZD4054 (targets endothelin A receptor) as compounds which inhibit chordoma cell lines to differing extents. We also assessed several kinase drug combinations, of these, afatinib (EGFR) and palbociclib (CDK4/6) as well as afatinib and AZD2014 showed substantial synergy against U-CH1 cells in vitro. Since each of these pairs of compounds likely have kinome inhibition profiles that are distinct from one another, co-dosing will allow us to target two key chordoma vulnerabilities simultaneously. Another advantage of working with these compounds is that pharmacokinetics data for in vivo studies is available. There is a growing body of data on the effects of small molecules on the growth of chordoma cell lines. The results of our studies indicate that machine learning approaches utilizing these data can help identify compounds suitable for testing in chordoma cell line models, and that we have identified combinations of inhibitors that act on different pathways important for chordoma cell growth which can behave synergistically. This work paves the way for future in vivo evaluation of CDK / mTOR inhibitor combinations in animal models of chordoma and then in the clinic. A treatment for chordoma would fill a dire unmet clinical need, and repurposing of available medicines is likely the quickest approach to approved treatments.

Table 4. Summary of drug combinations in U-CH1 cells. Each CI was calculated at the specified effect level, along with upper and lower confidence limits (UCL and LCL). Combinations with significant synergy are indicated in bold.

| Effect level | Drug 1       | Drug 2       | Ratio     | CI   | UCL  | LCL  |
|--------------|--------------|--------------|-----------|------|------|------|
| 50%          | Afatinib     | Palbociclib  | 0.009:1   | 0.58 | 0.79 | 0.43 |
|              |              |              | 0.038:1   | 0.43 | 0.66 | 0.28 |
|              |              |              | 0.15:1    | 0.48 | 0.96 | 0.25 |
| 50%          | Afatinib     | AZD0530      | 0.025:1   | 0.98 | 2.92 | 0.34 |
|              |              |              | 0.1:1     | 1.10 | 2.63 | 0.48 |
|              |              |              | 0.4:1     | 1.05 | 2.36 | 0.53 |
| 50%          | Afatinib     | AZD2014      | 0.075:1   | 0.51 | 0.78 | 0.34 |
|              |              |              | 0.3:1     | 0.57 | 0.84 | 0.39 |
|              |              |              | 1:2:1     | 0.75 | 1.14 | 0.50 |
| 50%          | Palbociclib  | AZD0530      | 0.67:1    | 1.08 | 1.62 | 0.72 |
|              |              |              | 2:7:1     | 0.95 | 1.14 | 0.79 |
|              |              |              | 11:1      | 0.77 | 0.88 | 0.67 |
| 75%          | Palbociclib  | AZD2014      | 2:1       | 1.432| 2.289| 0.895|
|              |              |              | 8:1       | 1.398| 1.911| 1.024|
|              |              |              | 32:1      | 1.248| 1.478| 1.053|
| 50%          | AZD0530      | AZD2014      | 0.75:1    | 0.61 | 0.77 | 0.49 |
|              |              |              | 3:1       | 0.81 | 0.99 | 0.66 |
|              |              |              | 12:1      | 1.19 | 1.50 | 0.94 |

Table 5. Summary of drug combinations in U-CH2 cells. Each CI was calculated at the specified effect level, along with upper and lower confidence limits (UCL and LCL). No combinations had significant synergy.

| Effect level | Drug 1       | Drug 2       | Ratio     | CI   | UCL  | LCL  |
|--------------|--------------|--------------|-----------|------|------|------|
| 50%          | Afatinib     | Palbociclib  | 0.096:1   | 0.68 | 1.45 | 0.33 |
|              |              |              | 0.38:1    | 0.52 | 1.76 | 0.25 |
|              |              |              | 1:5:1     | 0.59 | 5.47 | 0.40 |
| 50%          | Afatinib     | RDEA119      | 0.074:1   | 1.04 | 2.25 | 0.49 |
|              |              |              | 0.29:1    | 0.98 | 2.78 | 0.48 |
|              |              |              | 1:2:1     | 0.53 | > 10 | 0.36 |
| 75%          | Afatinib     | AZD2014      | 0.62:1    | 0.71 | 2.37 | 0.22 |
|              |              |              | 2:5:1     | 0.83 | 1.41 | 0.49 |
|              |              |              | 10:1      | 0.75 | 1.14 | 0.50 |
| 75%          | Palbociclib  | RDEA119      | 0.19:1    | 1.00 | > 10 | 0.33 |
|              |              |              | 0.76:1    | 0.57 | 5.60 | 0.06 |
|              |              |              | 3:1:1     | 0.38 | > 10 | 0.03 |
| 75%          | RDEA119      | AZD2014      | 2:1:1     | 1.77 | > 10 | 0.08 |
|              |              |              | 8:5:1     | 3.02 | > 10 | 1.16 |
|              |              |              | 34:1      | 1.63 | 4.97 | 0.54 |
**Methods**

**Compounds.** Palbociclib was obtained from Apexbio (Houston TX). Afatinib, AZD0530, RDEA11, AZD4654 and AZD2014 were obtained from Selleckchem (Houston, TX). Compounds were dissolved in DMSO, before dilution in cell culture media for cell-based assays.

**In vitro testing.** All chordoma cell lines were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM): Roswell Park Memorial Institute (RPMI) in a 4:1 ratio (Gibco, Life Technologies, NY, USA) and 10% fetal bovine serum (Seradigm, VWR, USA) at 37 °C, 5% CO₂ in 0.1% gelatin coated flasks. There were no media antibiotics used. Cell lines were then seeded with approximately 800 cells/well in 384 well gelatin coated plates and allowed to adhere overnight before the addition of drugs. Drugs were added in quadruplicate wells using a Tecan EVO150 with 96 MCA head (Tecan Group Ltd, Switzerland). Each plate included controls for drug solvation effects from DMSO. Plates were incubated with drugs for 48hrs prior to the addition of resazurin substrate (Alamar Blue, Biosource International, Camarillo California). Plates were then incubated for a further 18hrs before reading using an Infinite F200 microplate reader with a Connect Stacker (Tecan Group Ltd). iControl software (Version 1.11) was then used to measure the fluorescence intensity of resarufin at EX535nm and EM595nm. The resulting relative fluorescence units are proportional to cellular redox activity, which is a common proxy for the quantity of living cells.

After adjusting for the effects of DMSO in vehicle-only controls, raw fluorescence data was fitted to a four-parameter log-logistic dose response model. This model was constrained to fit a common upper asymptote for each individual experiment, and a positive lower asymptote. Each experiment was repeated for a total of 2–7 biological replicates, and estimated IC₅₀’s and maximal effects were combined using geometric and arithmetic means, respectively.

**Combination testing.** For synergy experiments, drugs were tested in combination using a fixed-ratio “ray” design⁶⁹. Drugs were diluted to 10× previously estimated IC₅₀ and combined in specific ratios (80%:20%, 50%:50% and 20%:80%). These combined drugs were serially diluted to maintain a constant ratio. Dose-response curves were fit for each mixture of drugs. Data from multiple biological replicates was combined in a mixed-effects model, using the function `metaDrC()` in the R package `medrc`.⁵⁸ Absolute IC₅₀ estimates from these models were then used to calculate the combination index CI = a/A + b/B, where A and B are doses of individual drugs that produce a specified effect, and (a, b) is the pair of doses in a combination that produces the same effect⁷⁰. Confidence intervals of CI were estimated using confidence limits of each IC₅₀ estimate in the same equation. CI < 1 indicates synergy, CI = 1 no effect, and CI > 1 antagonism.

**Software for machine learning.** Chordoma datasets were named as Broad²¹ and EGFR²⁰. These datasets consist of molecules screened against multiple cell lines and the original authors provided potency or activity classifications which were used as a binary score. These datasets underwent curation to remove problematic molecules before model building as described elsewhere¹⁰,¹²,²²-²⁹ to prepare and merge datasets collated in Molecular Notebook⁶⁰, as well as generate Bayesian models using ECFP6 descriptors⁶¹,⁶². Briefly, the Assay Central project includes automated workflows for curating well-defined structure–activity datasets that employ a set of rules for the detection of problematic data (i.e. abnormal valences, multiple components) that can be corrected by multiple means. Data that is compatible with machine learning is then used to generate a Bayesian model for prospective bioactivity predictions. Each Bayesian model in Assay Central includes the following metrics generated from fivefold cross validation: Recall, Precision, Specificity, F1-Score, Receiver Operating Characteristic (ROC) curve, Cohen’s Kappa (CK)⁶³,⁶⁴, and the Matthews Correlation Coefficient (MCC)⁶⁵. Assay Central prediction workflows assign a probability-like score⁶¹,⁶², with values above 0.5 considered an active prediction, and an applicability score which assesses the portion of fragments overlapping with the training set molecules to the input compounds. Predictions were applied to the specific compounds of interest from NCATS (https://web.archive.org/web/20170716163452/https://ncats.nih.gov/ntu/assets/2017#Adult_Indications) that were not in the training sets (AZD0530 was in the Broad dataset and was therefore not scored by the models) prior to in vitro testing as we have done previously²⁵.

**References**

1. Wollert, K. et al. Chordoma: current concepts, management, and future directions. *Lancet Oncol.* **13**, e69–76 (2012).
2. Stacchiotti, S., et al. Building a global consensus approach to chordoma: a position paper from the medical and patient community. *Lancet Oncol.* **16**, 71–83 (2015).
3. Sciuropa, D. M. et al. Chordoma of the sacrum and vertebral bodies. *J. Am. Acad. Orthop. Surg.* **17**, 708–717 (2009).
4. Yang, X. R. et al. *T* (brachyury) gene duplication confers major susceptibility to familial chordoma. *Nat. Genet.* **41**, 1176–1178 (2009).
5. Wu, R. et al. *T* (brachyury) gene duplication confers major susceptibility to familial chordoma. *Nat. Genet.* **41**, 1176–1178 (2009).
6. Pillay, N. et al. A common single-nucleotide variant in *T* is strongly associated with chordoma. *Nat. Genet.* **44**, 1185–1187 (2012).
7. Dahl, N. A. et al. Chordoma occurs in young children with tuberous sclerosis. *J. Neuropathol. Exp. Neurol.* **76**, 418–423 (2017).
8. de Castro, C. V. et al. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome. *Hum. Pathol.* **44**, 1747–1755 (2013).
55. MacDonald, A. et al. Phase I study of orally administered (14)Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies. *Cancer Chemother. Pharmacol.* **83**, 787–795 (2019).

56. Jack, J., Havener, T. M., McLeod, H. L., Motsinger-Reif, A. A. & Foster, M. Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations. *Pharmacogenomics* **16**, 1451–1463 (2015).

57. Gennings, C. et al. A novel flexible approach for evaluating fixed ratio mixtures of full and partial agonists. *Toxicol. Sci.* **80**, 134–150 (2004).

58. Ritz, C., Jensen, S. M., Gerhard, D. & Streibig, J. C. *Dose-Response Analysis Using R* 1st edn. (Chapman and Hall/CRC, Cambridge, 2019).

59. Foucquier, J. & Guedj, M. Analysis of drug combinations: current methodological landscape. *Pharmacol Res Perspect* **3**, e00149 (2015).

60. Clark AM. *Molecular Notebook*. http://molecularnotebook.com (2018).

61. Clark, A. M. et al. Open source bayesian models: 1. Application to ADME/Tox and drug discovery datasets. *J. Chem. Inf. Model* **55**, 1231–1245 (2015).

62. Clark, A. M. & Ekins, S. Open Source Bayesian Models: 2. Mining A “big dataset” to create and validate models with ChEMBL. *J. Chem. Inf. Model* **55**, 1246–1260 (2015).

63. Carletta, J. Assessing agreement on classification tasks: The kappa statistic. *Comput. Linguist.* **22**, 249–254 (1996).

64. Cohen, J. A coefficient of agreement for nominal scales. *Educ. Psychol. Meas.* **20**, 37–46 (1960).

65. Matthews, B. W. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. *Biochim. Biophys. Acta* **405**, 442–451 (1975).

66. Team RC. *R: A Language and Environment for Statistical Computing*. (R Foundation for Statistical Computing, Vienna, 2019).

**Acknowledgements**

We kindly acknowledge the support of Dr. Joan Levy with the Chordoma Foundation. SE kindly acknowledges NIH funding R44GM122196-02A1 from NIH NIGMS and FY2018 UNC Research Opportunities Initiative (ROI) Award. The SGC (DHD) is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, Takeda, and Wellcome [106169/ZZ14/Z]. The authors acknowledge the generous support provided by the Eshelman Institute of Innovation and the Bryson Foundation at the UNC Eshelman School of Pharmacy.” Dr. Alex Clark is acknowledged for assistance with Assay Central.

**Author contributions**

E.A and T.H. performed analyses of compounds in cell lines. K.M.Z. and D.H. F performed machine learning analyses. T.L. assisted with analyses. A.J.H. and S.E. directed the research, E.A., S.J.C., D.M., A.J.H. D.H.D. and S.E. wrote the manuscript.

**Competing interests**

T.L., K.M.Z., D.H.F. and S.E. are employees of Collaborations Pharmaceuticals, Inc. DHD is on the Board of Directors and Scientific Advisory Board of the Chordoma Foundation. All other authors do not have competing interests.

**Additional information**

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-70026-w. 

Correspondence and requests for materials should be addressed to S.E.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access] This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020